BORTDEXADARA Regimen
DVd - Darzalex + Velcade + dex - Myeloma | ChemoExperts
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
Dosing & Treatment Plan for VELCADE® (bortezomib)
Multiple myeloma current treatment algorithms | Blood Cancer Journal
3630-Multiple myeloma DVd (daratumumab bortezomib dexamethasone) overview | eviQ
VAD and similar alternate regimens | Download Table
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Multiple myeloma current treatment algorithms. - Abstract - Europe PMC
Treatment of relapsed and refractory multiple myeloma | Haematologica
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study - Yimer - 2019 - British Journal of Haematology - Wiley Online Library
Cancers | Free Full-Text | Recent Advances in the Treatment of Patients with Multiple Myeloma
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management - Rajkumar - 2018 - American Journal of Hematology - Wiley Online Library
Frontiers | Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8
Multiple myeloma current treatment algorithms | Blood Cancer Journal
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1
Multiple Myeloma - Oncologic Disorders - Pharmacotherapy A Pathophysiologic Approach, 9th Ed.
Approved for use in:
Treatment of relapsed and refractory multiple myeloma | Haematologica
JPM | Free Full-Text | Targeted Therapies for Multiple Myeloma
